Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Academic Article uri icon


  • Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially improved over the past decades, and impressive results have been obtained in recent preclinical and clinical trials. However, PDAC is likely the exception because of its unique tumour microenvironment (TME). In this review, we summarize the characteristics of the PDAC TME and focus on the network of various tumour-infiltrating immune cells, outlining the current advances in PDAC immunotherapy and addressing the effect of the PDAC TME on immunotherapy. This review further explores the combinations of different therapies used to enhance antitumour efficacy or reverse immunodeficiencies and describes optimizable immunotherapeutic strategies for PDAC. The concordant combination of various treatments, such as targeting cancer cells and the stroma, reversing suppressive immune reactions and enhancing antitumour reactivity, may be the most promising approach for the treatment of PDAC. Traditional treatments, especially chemotherapy, may also be optimized for individual patients to remodel the immunosuppressive microenvironment for enhanced therapy.

published proceedings

  • Mol Cancer

altmetric score

  • 0.5

author list (cited authors)

  • Fan, J., Wang, M., Chen, H., Shang, D., Das, J. K., & Song, J.

citation count

  • 76

complete list of authors

  • Fan, Jia-Qiao||Wang, Meng-Fei||Chen, Hai-Long||Shang, Dong||Das, Jugal K||Song, Jianxun

publication date

  • January 2020